A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1
A phase 2 trial of Carboplatin, Bevacizumab, Olaparib in ovarian cancer, run by AbbVie, now recruiting.
Overview
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies is a phase 2 interventional study registered as NCT07024784 by AbbVie, with 377 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-01. Interventions recorded: IMGN151, Carboplatin, Bevacizumab, Olaparib. Conditions listed: Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
- TrialA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
- TrialMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov
Shares AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Ovarian cancer.
- TrialStudy to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
Shares Olaparib, Carboplatin, Ovarian cancer.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares Olaparib, Ovarian cancer.
- TrialD9319C00001- 1L OC Mono Global RCT
Shares Olaparib, Ovarian cancer.
- TrialWoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Shares Olaparib, Ovarian cancer.